{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:34:31Z","timestamp":1788975271086,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hepatic sinusoidal obstruction syndrome (SOS) represents a serious complication following hematopoietic stem cell transplantation (HSCT). Our study aimed to investigate important risk factors of SOS in a pediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 105 children, adolescents and young adults who underwent allogeneic HSCT at our pediatric HSCT center in Jena. The observation period was 12\u00a0years and SOS was defined by the pediatric criteria of the European Society for Blood and Marrow Transplantation (EBMT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      15 out of all 105 patients developed SOS (14.3%). The median time from HSCT to SOS diagnosis was 12\u00a0days. The mortality rate of SOS was 20.0%. In univariate analyses, we identified the significant risk factors of patient age\u2009&lt;\u20091\u00a0year [odds ratio (OR)\u2009=\u20097.25,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.037], prior treatment with gemtuzumab ozogamicin (OR\u2009=\u200911.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020), high pretransplant ferritin levels above 1500\u00a0ng\/mL (OR\u2009=\u20094.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033), 2000\u00a0ng\/mL (OR\u2009=\u20094.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016), and 2400\u00a0ng\/mL (OR\u2009=\u20095.29,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) as well as international normalized ratio (INR)\u2009\u2265\u20091.3 (OR\u2009=\u20095.91,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). The following risk factors could be confirmed in multivariate analysis: treatment with gemtuzumab ozogamicin (OR\u2009=\u20099.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048), ferritin\u2009&gt;\u20092400\u00a0ng\/mL (OR\u2009=\u20095.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023), and INR\u2009\u2265\u20091.3 (OR\u2009=\u20098.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study confirms several risk factors from the current literature. Additionally, this is the first report on the risk factor of high pretransplant INR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-021-03732-1","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T04:02:57Z","timestamp":1626148977000},"page":"1447-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients"],"prefix":"10.1007","volume":"148","author":[{"given":"Jaspar","family":"Kloehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Brodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-0075","authenticated-orcid":false,"given":"Bernd","family":"Gruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"3732_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ajh.23188","volume":"87","author":"P Armand","year":"2012","unstructured":"Armand P et al (2012) Does iron overload really matter in stem cell transplantation? Am J Hematol 87:569\u2013572. https:\/\/doi.org\/10.1002\/ajh.23188","journal-title":"Am J Hematol"},{"key":"3732_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","volume":"32","author":"CC Barker","year":"2003","unstructured":"Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS (2003) Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transpl 32:79\u201387. https:\/\/doi.org\/10.1038\/sj.bmt.1704069","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1084-2756(03)00066-6","volume":"8","author":"SV Beath","year":"2003","unstructured":"Beath SV (2003) Hepatic function and physiology in the newborn. Semin Neonatol 8:337\u2013346. https:\/\/doi.org\/10.1016\/s1084-2756(03)00066-6","journal-title":"Semin Neonatol"},{"key":"3732_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16557","author":"MS Cairo","year":"2020","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N (2020) Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.16557","journal-title":"Br J Haematol"},{"key":"3732_CR5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M (2011) The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transpl 46:1495\u20131502. https:\/\/doi.org\/10.1038\/bmt.2011.65","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR6","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E et al (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Eur Group Blood Marrow Transp Chronic Leuk Work Party Blood 92:3599\u20133604","journal-title":"Eur Group Blood Marrow Transp Chronic Leuk Work Party Blood"},{"key":"3732_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, D\u00edaz-Bey\u00e1 M, Rosi\u00f1ol L, Mart\u00ednez C, Fern\u00e1ndez-Avil\u00e9s F, Rovira M (2011) The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl 17:1713\u20131720. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.006","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR8","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S et al (2005) A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 90:1396\u20131404","journal-title":"Haematologica"},{"key":"3732_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","volume":"40","author":"DKL Cheuk","year":"2007","unstructured":"Cheuk DKL, Wang P, Lee TL, Chiang AKS, Ha SY, Lau YL, Chan GCF (2007) Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transpl 40:935\u2013944. https:\/\/doi.org\/10.1038\/sj.bmt.1705835","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0268-960x(03)00002-x","volume":"17","author":"JA Coppell","year":"2003","unstructured":"Coppell JA, Brown SA, Perry DJ (2003) Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 17:63\u201370. https:\/\/doi.org\/10.1016\/s0268-960x(03)00002-x","journal-title":"Blood Rev"},{"key":"3732_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA et al (2010) Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl 16:157\u2013168. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379:1301\u20131309. https:\/\/doi.org\/10.1016\/s0140-6736(11)61938-7","journal-title":"Lancet"},{"key":"3732_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","volume":"22","author":"S Corbacioglu","year":"2016","unstructured":"Corbacioglu S et al (2016) Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transpl 22:1874\u20131882. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.001","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S et al (2018) Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl 53:138\u2013145. https:\/\/doi.org\/10.1038\/bmt.2017.161","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M (2019) Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transpl 25:1271\u20131280. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"J-H Dalle","year":"2016","unstructured":"Dalle J-H, Giralt SA (2016) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl 22:400\u2013409. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.510290615","volume":"29","author":"LD DeLeve","year":"1999","unstructured":"DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB, Kanel GC (1999) Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 29:1779\u20131791. https:\/\/doi.org\/10.1002\/hep.510290615","journal-title":"Hepatology"},{"key":"3732_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"LD DeLeve","year":"2002","unstructured":"DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:27\u201342. https:\/\/doi.org\/10.1055\/s-2002-23204","journal-title":"Semin Liver Dis"},{"key":"3732_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbmt.2018.09.027","volume":"25","author":"M Faraci","year":"2019","unstructured":"Faraci M et al (2019) Sinusoidal obstruction syndrome\/Veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. Biol Blood Marrow Transpl 25:313\u2013320. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.027","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR20","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","volume":"92","author":"H H\u00e4gglund","year":"1998","unstructured":"H\u00e4gglund H, Remberger M, Klaesson S, L\u00f6nnqvist B, Ljungman P, Ringd\u00e9n O (1998) Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 92:4568\u20134572","journal-title":"Blood"},{"key":"3732_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bmt.1701506","volume":"22","author":"S Hasegawa","year":"1998","unstructured":"Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, Hirabayashi N (1998) Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transpl 22:1191\u20131197. https:\/\/doi.org\/10.1038\/sj.bmt.1701506","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ et al (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778\u2013783. https:\/\/doi.org\/10.1097\/00007890-198712000-00011","journal-title":"Transplantation"},{"key":"3732_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.bmt.1700895","volume":"20","author":"M Kami","year":"1997","unstructured":"Kami M et al (1997) Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution. Bone Marrow Transpl 20:397\u2013402. https:\/\/doi.org\/10.1038\/sj.bmt.1700895","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41409-018-0426-8","volume":"54","author":"MB Kammersgaard","year":"2019","unstructured":"Kammersgaard MB, Kielsen K, Heilmann C, Ifversen M, M\u00fcller K (2019) Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome. Bone Marrow Transpl 54:1406\u20131418. https:\/\/doi.org\/10.1038\/s41409-018-0426-8","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1055\/s-0038-1657371","volume":"49","author":"TB Kirkwood","year":"1983","unstructured":"Kirkwood TB (1983) Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 49:238\u2013244","journal-title":"Thromb Haemost"},{"key":"3732_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1182\/blood-2009-03-212282","volume":"114","author":"SC Maradei","year":"2009","unstructured":"Maradei SC, Maiolino A, de Azevedo AM, Colares M, Bouzas LF, Nucci M (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation Blood. J Am Soc Hematol 114:1270\u20131275. https:\/\/doi.org\/10.1182\/blood-2009-03-212282","journal-title":"J Am Soc Hematol"},{"key":"3732_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12185-014-1578-y","volume":"99","author":"N Maximova","year":"2014","unstructured":"Maximova N et al (2014) Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant. Int J Hematol 99:766\u2013772. https:\/\/doi.org\/10.1007\/s12185-014-1578-y","journal-title":"Int J Hematol"},{"key":"3732_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED (1984) Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4:116\u2013122. https:\/\/doi.org\/10.1002\/hep.1840040121","journal-title":"Hepatology"},{"key":"3732_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB et al (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255\u2013267. https:\/\/doi.org\/10.7326\/0003-4819-118-4-199302150-00003","journal-title":"Ann Intern Med"},{"key":"3732_CR30","first-page":"63","volume":"17","author":"P McKay","year":"1996","unstructured":"McKay P, Murphy J, Cameron S, Burnett A, Campbell M, Tansey P, Franklin I (1996) Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transpl 17:63\u201366","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.bmt.1705340","volume":"37","author":"M Miceli","year":"2006","unstructured":"Miceli M et al (2006) Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transpl 37:857\u2013864. https:\/\/doi.org\/10.1038\/sj.bmt.1705340","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M et al (2015) Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives: a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 50:781\u2013789. https:\/\/doi.org\/10.1038\/bmt.2015.52","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M et al (2016) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl 51:906\u2013912. https:\/\/doi.org\/10.1038\/bmt.2016.130","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M et al (2020) Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl 55:485\u2013495. https:\/\/doi.org\/10.1038\/s41409-019-0705-z","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/10245332.1999.11746478","volume":"4","author":"M Morado","year":"1999","unstructured":"Morado M et al (1999) Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospect Cohort Study Hematol 4:505\u2013512. https:\/\/doi.org\/10.1080\/10245332.1999.11746478","journal-title":"Prospect Cohort Study Hematol"},{"key":"3732_CR36","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/pbc.21425","volume":"50","author":"A Qureshi","year":"2008","unstructured":"Qureshi A, Marshall L, Lancaster D (2008) Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 50:831\u2013832. https:\/\/doi.org\/10.1002\/pbc.21425","journal-title":"Pediatr Blood Cancer"},{"key":"3732_CR37","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood.v99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P, Shulman HM, Sievers EL, McDonald GB (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy Blood. J Am Soc Hematol 99:2310\u20132314. https:\/\/doi.org\/10.1182\/blood.v99.7.2310","journal-title":"J Am Soc Hematol"},{"key":"3732_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1055\/s-2005-923315","volume":"25","author":"GA Ramm","year":"2005","unstructured":"Ramm GA, Ruddell RG (2005) Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 25:433\u2013449. https:\/\/doi.org\/10.1055\/s-2005-923315","journal-title":"Semin Liver Dis"},{"key":"3732_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41408-020-0286-5","volume":"10","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Corbacioglu S (2020) Veno-occlusive disease\/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J 10:29. https:\/\/doi.org\/10.1038\/s41408-020-0286-5","journal-title":"Blood Cancer J"},{"key":"3732_CR40","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG et al (2016) Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127:1656\u20131665. https:\/\/doi.org\/10.1182\/blood-2015-10-676924","journal-title":"Blood"},{"key":"3732_CR41","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00432-014-1857-2","volume":"141","author":"C Seifert","year":"2015","unstructured":"Seifert C, Wittig S, Arndt C, Gruhn B (2015) Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 141:877\u2013885. https:\/\/doi.org\/10.1007\/s00432-014-1857-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"3732_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102827","volume":"59","author":"N Soyer","year":"2020","unstructured":"Soyer N et al (2020) Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of Turkish Hematology Research and Education Group (ThREG). Transfus Apheresis Sci 59:102827. https:\/\/doi.org\/10.1016\/j.transci.2020.102827","journal-title":"Transfus Apheresis Sci"},{"key":"3732_CR43","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2003-11-3778","volume":"104","author":"A Srivastava","year":"2004","unstructured":"Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104:1574\u20131577. https:\/\/doi.org\/10.1182\/blood-2003-11-3778","journal-title":"Blood"},{"key":"3732_CR44","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","volume":"24","author":"C Strouse","year":"2018","unstructured":"Strouse C et al (2018) Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl 24:2072\u20132080. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.013","journal-title":"Biol Blood Marrow Transpl"},{"key":"3732_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0049-3848(95)00061-u","volume":"78","author":"A Tripodi","year":"1995","unstructured":"Tripodi A, Chantarangkul V, Akkawat B, Clerici M, Mannucci PM (1995) A partial factor V deficiency in anticoagulated lyophilized plasmas has been identified as a cause of the international normalized ratio discrepancy in the external quality assessment scheme. Thromb Res 78:283\u2013292. https:\/\/doi.org\/10.1016\/0049-3848(95)00061-u","journal-title":"Thromb Res"},{"key":"3732_CR46","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M et al (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102:1578\u20131582. https:\/\/doi.org\/10.1182\/blood-2003-01-0255","journal-title":"Blood"},{"key":"3732_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K et al (2016) Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl 51:403\u2013409. https:\/\/doi.org\/10.1038\/bmt.2015.283","journal-title":"Bone Marrow Transpl"},{"key":"3732_CR48","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","volume":"54","author":"J-H Yoon","year":"2019","unstructured":"Yoon J-H et al (2019) Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD). Bone Marrow Transpl 54:1361\u20131368. https:\/\/doi.org\/10.1038\/s41409-019-0492-6","journal-title":"Bone Marrow Transpl"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03732-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T03:05:29Z","timestamp":1652756729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3732"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03732-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-374214\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards. The study was approved by the ethics committee at the University Hospital of the Friedrich Schiller University at Jena (2021\u20132060). Informed consent was obtained from all individual participants or the responsible persons included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}